---
document_datetime: 2025-12-29 09:36:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vyepti.html
document_name: vyepti.html
version: success
processing_time: 0.1077888
conversion_datetime: 2025-12-30 02:55:29.405281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vyepti

[RSS](/en/individual-human-medicine.xml/67517)

##### Authorised

This medicine is authorised for use in the European Union

eptinezumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vyepti](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vyepti is a medicine used to prevent migraine in adults who have migraines at least 4 days a month.

Vyepti contains the active substance eptinezumab.

Expand section

Collapse section

## How is Vyepti used?

The medicine can only be obtained with a prescription. Treatment should be started and monitored by healthcare professionals experienced in the diagnosis and treatment of migraine.

Vyepti is given by infusion (drip) into a vein over 30 minutes once every 12 weeks. The recommended dose is 100 mg. This dose may be increased to 300 mg, depending on how the patient responds.

For more information about using Vyepti, see the package leaflet or contact your doctor or pharmacist.

## How does Vyepti work?

A substance in the body called calcitonin gene-related peptide (CGRP) contributes to the development of migraine. The [active substance](/en/node/43123) in Vyepti, eptinezumab, is a monoclonal antibody (a type of protein) designed to attach to CGRP and prevent it from binding to its target on the body's cells, thereby helping to prevent migraines from occurring.

## What benefits of Vyepti have been shown in studies?

Two main studies showed that Vyepti is effective at reducing the number of days patients suffer from migraines.

The first was a 48-week study involving 898 adults who had at least 4 migraine days a month and between 4 to 14 headache days a month. Those treated with 100 mg or 300 mg Vyepti had around 4 fewer days with migraines per month during the first 12 weeks of treatment, compared with 3 fewer days for patients on placebo (dummy treatment).

The second was a 24-week study involving 1,121 adults who had migraines for at least 8 days a month and between 15 and 26 headache days a month. Those treated with 100 mg or 300 mg Vyepti had on average 8 fewer days with migraines per month during the first 12 weeks of treatment compared with around 6 fewer days for patients on placebo.

## What are the risks associated with Vyepti?

The most common side effects with Vyepti (which may affect up to 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat), hypersensitivity (allergic) reactions and tiredness.

For the full list of side effects of Vyepti, see the package leaflet.

## Why is Vyepti authorised in the EU?

The European Medicines Agency decided that Vyepti's benefits are greater than its risks and it can be authorised for use in the EU. Two main studies have shown that Vyepti is effective at reducing the number of days patients suffer from migraines. The side effects are considered manageable.

## What measures are being taken to ensure the safe and effective use of Vyepti?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vyepti have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vyepti are continuously monitored. Suspected side effects reported with Vyepti are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vyepti

Vyepti received a marketing authorisation valid throughout the EU on 24 January 2022.

Vyepti : EPAR - Medicine Overview

Reference Number: EMA/10001/2022

English (EN) (115.19 KB - PDF)

**First published:** 15/02/2022

[View](/en/documents/overview/vyepti-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-645)

български (BG) (140.44 KB - PDF)

**First published:**

15/02/2022

[View](/bg/documents/overview/vyepti-epar-medicine-overview_bg.pdf)

español (ES) (115.15 KB - PDF)

**First published:**

15/02/2022

[View](/es/documents/overview/vyepti-epar-medicine-overview_es.pdf)

čeština (CS) (136.5 KB - PDF)

**First published:**

15/02/2022

[View](/cs/documents/overview/vyepti-epar-medicine-overview_cs.pdf)

dansk (DA) (115.53 KB - PDF)

**First published:**

15/02/2022

[View](/da/documents/overview/vyepti-epar-medicine-overview_da.pdf)

Deutsch (DE) (118.27 KB - PDF)

**First published:**

15/02/2022

[View](/de/documents/overview/vyepti-epar-medicine-overview_de.pdf)

eesti keel (ET) (103.83 KB - PDF)

**First published:**

15/02/2022

[View](/et/documents/overview/vyepti-epar-medicine-overview_et.pdf)

ελληνικά (EL) (139.9 KB - PDF)

**First published:**

15/02/2022

[View](/el/documents/overview/vyepti-epar-medicine-overview_el.pdf)

français (FR) (115.85 KB - PDF)

**First published:**

15/02/2022

[View](/fr/documents/overview/vyepti-epar-medicine-overview_fr.pdf)

hrvatski (HR) (136.52 KB - PDF)

**First published:**

15/02/2022

[View](/hr/documents/overview/vyepti-epar-medicine-overview_hr.pdf)

italiano (IT) (114.39 KB - PDF)

**First published:**

15/02/2022

[View](/it/documents/overview/vyepti-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (144.97 KB - PDF)

**First published:**

15/02/2022

[View](/lv/documents/overview/vyepti-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (136.38 KB - PDF)

**First published:**

15/02/2022

[View](/lt/documents/overview/vyepti-epar-medicine-overview_lt.pdf)

magyar (HU) (135.72 KB - PDF)

**First published:**

15/02/2022

[View](/hu/documents/overview/vyepti-epar-medicine-overview_hu.pdf)

Malti (MT) (139.4 KB - PDF)

**First published:**

15/02/2022

[View](/mt/documents/overview/vyepti-epar-medicine-overview_mt.pdf)

Nederlands (NL) (115.67 KB - PDF)

**First published:**

15/02/2022

[View](/nl/documents/overview/vyepti-epar-medicine-overview_nl.pdf)

polski (PL) (140.01 KB - PDF)

**First published:**

15/02/2022

[View](/pl/documents/overview/vyepti-epar-medicine-overview_pl.pdf)

português (PT) (116.34 KB - PDF)

**First published:**

15/02/2022

[View](/pt/documents/overview/vyepti-epar-medicine-overview_pt.pdf)

română (RO) (134.61 KB - PDF)

**First published:**

15/02/2022

[View](/ro/documents/overview/vyepti-epar-medicine-overview_ro.pdf)

slovenčina (SK) (135.92 KB - PDF)

**First published:**

15/02/2022

[View](/sk/documents/overview/vyepti-epar-medicine-overview_sk.pdf)

slovenščina (SL) (135.22 KB - PDF)

**First published:**

15/02/2022

[View](/sl/documents/overview/vyepti-epar-medicine-overview_sl.pdf)

Suomi (FI) (113.5 KB - PDF)

**First published:**

15/02/2022

[View](/fi/documents/overview/vyepti-epar-medicine-overview_fi.pdf)

svenska (SV) (114.6 KB - PDF)

**First published:**

15/02/2022

[View](/sv/documents/overview/vyepti-epar-medicine-overview_sv.pdf)

Vyepti : EPAR - Risk management plan summary

English (EN) (208.89 KB - PDF)

**First published:** 15/02/2022

[View](/en/documents/rmp-summary/vyepti-epar-risk-management-plan-summary_en.pdf)

## Product information

Vyepti : EPAR - Product information

English (EN) (616.68 KB - PDF)

**First published:** 15/02/2022

**Last updated:** 16/10/2024

[View](/en/documents/product-information/vyepti-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-928)

български (BG) (711.67 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/bg/documents/product-information/vyepti-epar-product-information_bg.pdf)

español (ES) (665.89 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/es/documents/product-information/vyepti-epar-product-information_es.pdf)

čeština (CS) (692.85 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/cs/documents/product-information/vyepti-epar-product-information_cs.pdf)

dansk (DA) (749.39 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/da/documents/product-information/vyepti-epar-product-information_da.pdf)

Deutsch (DE) (752.56 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/de/documents/product-information/vyepti-epar-product-information_de.pdf)

eesti keel (ET) (722.12 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/et/documents/product-information/vyepti-epar-product-information_et.pdf)

ελληνικά (EL) (710.14 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/el/documents/product-information/vyepti-epar-product-information_el.pdf)

français (FR) (655.3 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/fr/documents/product-information/vyepti-epar-product-information_fr.pdf)

hrvatski (HR) (785.89 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/hr/documents/product-information/vyepti-epar-product-information_hr.pdf)

íslenska (IS) (637.12 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/is/documents/product-information/vyepti-epar-product-information_is.pdf)

italiano (IT) (734.28 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/it/documents/product-information/vyepti-epar-product-information_it.pdf)

latviešu valoda (LV) (746.7 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/lv/documents/product-information/vyepti-epar-product-information_lv.pdf)

lietuvių kalba (LT) (585.87 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/lt/documents/product-information/vyepti-epar-product-information_lt.pdf)

magyar (HU) (778.41 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/hu/documents/product-information/vyepti-epar-product-information_hu.pdf)

Malti (MT) (791.46 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/mt/documents/product-information/vyepti-epar-product-information_mt.pdf)

Nederlands (NL) (757.31 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/nl/documents/product-information/vyepti-epar-product-information_nl.pdf)

norsk (NO) (710.6 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/no/documents/product-information/vyepti-epar-product-information_no.pdf)

polski (PL) (801.98 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/pl/documents/product-information/vyepti-epar-product-information_pl.pdf)

português (PT) (725.34 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/pt/documents/product-information/vyepti-epar-product-information_pt.pdf)

română (RO) (759.89 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/ro/documents/product-information/vyepti-epar-product-information_ro.pdf)

slovenčina (SK) (805.43 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/sk/documents/product-information/vyepti-epar-product-information_sk.pdf)

slovenščina (SL) (793.51 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/sl/documents/product-information/vyepti-epar-product-information_sl.pdf)

Suomi (FI) (732.96 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/fi/documents/product-information/vyepti-epar-product-information_fi.pdf)

svenska (SV) (725.24 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

16/10/2024

[View](/sv/documents/product-information/vyepti-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0020 12/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vyepti : EPAR - All authorised presentations

English (EN) (58.49 KB - PDF)

**First published:** 15/02/2022

**Last updated:** 12/12/2023

[View](/en/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-213)

български (BG) (93.75 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/bg/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_bg.pdf)

español (ES) (55.56 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/es/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_es.pdf)

čeština (CS) (74.46 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/cs/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (57.62 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/da/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (57.8 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/de/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (54.39 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/et/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.35 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/el/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_el.pdf)

français (FR) (55.57 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/fr/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (116.31 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/hr/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (56.46 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/is/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.59 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/it/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (72.82 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/lv/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (73.55 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/lt/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (66.3 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/hu/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (73.38 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/mt/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (55.27 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/nl/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (57 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/no/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_no.pdf)

polski (PL) (78.81 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/pl/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_pl.pdf)

português (PT) (56.76 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/pt/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_pt.pdf)

română (RO) (74.37 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/ro/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (72.3 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/sk/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (64.73 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/sl/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/fi/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (56.01 KB - PDF)

**First published:**

15/02/2022

**Last updated:**

12/12/2023

[View](/sv/documents/all-authorised-presentations/vyepti-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vyepti Active substance Eptinezumab International non-proprietary name (INN) or common name eptinezumab Therapeutic area (MeSH) Migraine Disorders Anatomical therapeutic chemical (ATC) code N02CD

### Pharmacotherapeutic group

Analgesics

### Therapeutic indication

Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

## Authorisation details

EMA product number EMEA/H/C/005287 Marketing authorisation holder

H. Lundbeck A/S

Ottiliavej 9

Opinion adopted 11/11/2021 Marketing authorisation issued 24/01/2022 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vypeti : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (167.3 KB - PDF)

**First published:** 25/07/2022

**Last updated:** 16/10/2024

[View](/en/documents/procedural-steps-after/vypeti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vyepti-H-C-005287-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/378890/2024

English (EN) (2.05 MB - PDF)

**First published:** 10/10/2024

[View](/en/documents/variation-report/vyepti-h-c-005287-p46-006-epar-assessment-report_en.pdf)

Vyepti-H-C-005287-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/399588/2023

English (EN) (4.47 MB - PDF)

**First published:** 20/11/2023

[View](/en/documents/variation-report/vyepti-h-c-005287-p46-005-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Vyepti : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/9446/2022

English (EN) (5.38 MB - PDF)

**First published:** 15/02/2022

[View](/en/documents/assessment-report/vyepti-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vyepti

Adopted

English (EN) (102.03 KB - PDF)

**First published:** 12/11/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vyepti_en.pdf)

#### News on Vyepti

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-november-2021) 12/11/2021

**This page was last updated on** 16/10/2024

## Share this page

[Back to top](#main-content)